Pharma & Biotech

As the United States continues its battle against the devastating opioid crisis, Emergent BioSolutions is pursuing a distinctive strategy that...

Precision BioSciences Inc. shares extended their recent decline, closing the latest trading session with significant losses. The clinical-stage biotechnology company's...

Investors in Ionis Pharmaceuticals experienced a surprising market reaction following the long-awaited FDA approval of Dawnzera. Instead of triggering a...

While numerous biotech equities continue to struggle in weak markets, Arcus Biosciences is demonstrating a notable trend: major institutional investors...

Oric Pharmaceuticals Inc is entering a pivotal period, with a series of key investor conferences scheduled for September designed to...

Nuvectis Pharma is making significant strides with its promising drug candidate, NXP900. The biopharmaceutical company has successfully completed a Phase...

In a notable strategic departure, biopharmaceutical firm Ocugen has announced a $5 million equity investment in fellow biotechnology company Carisma...

enVVeno Medical's stock continued its dramatic descent on Friday, registering an additional 8.14% decline. This sustained sell-off was triggered by...

Australian biotechnology firm Immuron has initiated an unusually proactive communication strategy as it approaches two critical clinical milestones. The developer...

Pulmatrix Inc. is executing a profound strategic transformation, marked by its pending merger with Cullgen and the complete divestiture of...